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ABSTRACT 
Traditional systems of medicine all over the world even traditional medicine and cancer have been using plants and plants products 
for therapeutic intention. The purpose of these retrospective trials is to assess the clinical efficacy of chemotherapy in conjunction 
with TCM for a broad variety of cancers. 75 patients with available cancers were concluded in the study during September1993 – 
May 2018.The sex ratio of male: female was 50:25 respectively. The mean age at onset was 46.9 years（range 10-79 years. All 
patients were treated with different dosage of various chemotherapy in combination with TCM or traditional medicine alone. The 
basic chemotherapeutic regimen consisted of vincristine（VCR, 1-2 mg/week)、cyclophosphamide（CTX, 200-1, 000mg/ week), 
mitomycin C(MMC, 2-4mg/week) and 5-fluorouracil（5-Fu,250-500mg/ day). In addition, according to patient condition, the 
additional drug doxorubicin（ADM, 20mg/ week）in lymphoma and metastatic breast cancer, demethylcantharidin in liver cancer 
and cisplatin (DDP) or interleukin-2（PHA）or gefitinib in lung cancer. The detail prescription of TCM varied among a broad 
variety of carcinomas. The criteria of complete remission（CR）and/or partial remission（PR）is according to the rules where 
physicians have in common with in clinics. In 75 cases, the CR was obtained in 33(44%) advanced cancers, a short CR in 
11(14.7%) cases, PR in 25 (33.3%) cancers, stable disease in 6 cases. In differential types of 20 patients over ten years, lymphoma 
occupied 8 cases (40%). As to approach to the schedule of drug administration, 16 lymphoma obtained CR via COMA (CTX, 
VCR,  MMC, and ADM) regimen and TCM or antibiotics and immunotherapy. Five advanced gastric cancer were successfully 
treated using MFC and cinobufacini/  cantharidin, and TCM. In follow up, one HCC accompanied with colon polyps obtained CR 
via hepatectomy and targeting oncogenic receptor tyrosine kinase inhibitor sorafenib. Among two lung cancer, one female with 
metastatic lung cancer was given targeting oncogenic receptor EGFR gefitinib therapy after the combination chemotherapy, which 
was stable disease for 8+months. CR can also be achieved in one advanced cholangicarcinoma and one advanced gallbladder 
cancer through major protocol of TCM and the addition of small dosage of chemotherapy. Thyroid cancer was placed on the 
primary use of TCM. The crude herbs consisted of sargassum, tangle, Oyster（mussels), Poria cocos, Ophiopogon japonicus, 
Prunella vulgaris, Taraxacum, Scrophularia ningpoensis, Cremastra appendiculata, Trichosanthes Kirilowii, Sophora 
subprostrata, Houttuynia cordata, Scutellaria barbata d. don and Oldenlandia diffusa roxb. Among those long-term survivors, 31 
carcinomas obtained in disease-free survival over 5 years, 20 cancers were survival over 10 years, the longest four patients over 25 
years. In this study, it was experienced that a CR was a pivotal influencing factor in those longest survival patients, and traditional 
medicine was also recommended. Down regulating oncogenic receptors may be useful paradigm and perspective in currently the 
third line setting of clinical target therapy and in rendering our better understanding of cancer biology. 
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Chemotherapy is a major skillful of cancer therapy. 
One of the most important advances in oncology has 
been increased acceptance of evidence that most 
patients with disseminated tumors were setted to the 




medicine（TCM）and/or adoptive immunotherapy 
(LAK cells, TIL therapy)
15,16
. The experience in 
Ugandan children with Hodgkin's disease has been 
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excellent and in a study of 14 adults with stage I and II 
Hodgkin's disease, mostly clinically staged, 13 patients 
(93%) achieved CR with combination chemotherapy 
and all were in CR 11 to 94 months after the 
completion of treatment
17
. Another, a disease-free 
survivors of 5 years(56.5-59.3% versus 22-24.3%) and 
10 years (48.9%) was remarkably higher rate in those 
breast cancers with stage III following surgery plus 
chemotherapy than only surgery. More promising, in 
large trials of 48 HER2-positive early breast cancer 
patients, targeting the adjuvant trastuzumab treatment 
demonstrated highly favorable outcome. Five year 
overall survival rates and disease-free survival rates 
were 95.8% and 93.8% respectively
19
. Recently, 
neratinib was recently approved by FDA for extended 





Others, advanced or metastatic gastric cancer 
constitutes the majority of patients in clinical practice. 
Systemic chemotherapies and combined regimens are 
currently available, provides palliation and prolongs 
survival. In particular, high-quality clinical trials on 
TCM in cancer are generally lacking, except for 
Kampo medication for Japanese cancer patients
21,22
, 
arsenic trioxide (As2O3) in the role of acute 
promyelocytic leukemia
23
 and cantharidin in treatment 
of liver cancer
24
. This paper will attempt to place in 
proper interpretative review from those patients with 
cancers under remission in this group. 
 
MATERIALS AND METHODS 
75 patients with available cancers were concluded in 
the study during September 1993- May 2018. The sex 
ratio of male: female was 50:25 respectively. The mean 
age at onset was 46.9 years ranging from 10 to 79 yrs. 
Among age distribution, although there is some 
uncertain about the type distribution of cancers, it was 
found 38.1 years as the mean age at onset for 
lymphoma, 44.0 years for liver cancer, while higher 
mean age at 60.1 years has been shown in lung cancer 
in this group. The clinical diagnoses in a broad variety 
of carcinomas consisted of metastatic nasopharyngeal 
cancer 5 cases, metastatic breast cancer 4, lung tumors 
12,hepatocellular carcinoma(HCC) 12, stomach cancer 
5,hematological malignancies 25 cases(acute leukemias 
FAB M1 type 2, M2 type 1, acute promyelocytic 
leukemia 1,chronic myeloid leukemia CML 2,chronic 
lymphocytic leukemia CLL 1,multiple myeloma 
2,lymphoma 16), thyroid cancer 2, maxillary sinus 
carcinoma 1,carcinoma of mandibular sinus 2, 
laryngeal carcinoma 1, gallbladder cancer 1, 
cholangiocarcinoma 1, metastatic oral cancer 1, 
epidermoid carcinoma 1, replapsed vulvar cancer 1, 
and other metastatic sternal and spinal (T12) tumor 1 
respectively. All other benign neoplasias were not 
statistically included. The basic chemotherapeutic 
regimen consisted of vincristine（VCR, 1-2 mg/wk), 
cyclophosphamide（CTX, 200-1, 000 mg/wk), 
mitomycin C（MMC, 2-4 mg/wk) and 5-
fluorouracil（5-Fu, 250-500mg/day). In addition, the 
additional drug adriamycin (ADM, 20mg/wk）in 
lymphoma and metastatic breast cancer, demethyl 
cantharidin in liver cancer and cisplatin (DDP) or 
interleukin-2（PHA/ gefitinib in lung cancer. The 
detail prescription of TCM varied among a broad 
variety of carcinomas (see full text case reports).The 
criteria of complete remission (CR) and/or partial 
remission (PR) is according to the rules where 
physicians have in common with in clinics.  
Complete remission (CR): there was no more tumor 
or tumor complete regressed in patients for at least 1 
month;  
Partial remission: the tumor decreased by more than 
50% in patients for at least 1 month;  
Stable disease: the tumor decreased by less than 50% 
or increased by no more than 25% in patients;  
Disease progression: the tumor increased by more 
than 25% in patients, or new lesions emerged. The 
efficacy was evaluated according to the survival time 
from the day when patients were at onset. The clinical 
data for liver cancer
25,26






In 75 cancers, the rate of complete 
remission（CR）was achieved in 33(44%) advanced 
cancers. All CR patients with advanced cancers was 
survival over 5 years, 18 cancers was survival 10 years. 
Another, a short CR was obtained in 11 (14.7%) 
advanced cancers, the survival time varied from 20 
months to 4 yrs. PR was obtained in 25(33.3%) patients 
with a broad variety of carcinoma, while three 
patients（1 malignant lymphoma,1 carcinoma of 
mandibular sinus, 1 metastatic tumor of bone）had 
survival 12, 18+ and 11+ years respectively, 
implicating a longer survivor in patients the survival 
with tumours. Otherwise, stable disease was 6 cases. 
Basic characteristics of studied population were 
summarized in Table 1. 
During the schedule of drug administration, all patients 
were treated with the different dosage of 1 to 4 courses 
of various combination chemotherapy in conjunction 
with traditional medicine. In statistically analysis, one 
patient with nasophyaryngeal cancer, the diplopia and 
unable version in his eye were recovered to "normal" 
visual acuity following the combination chemotherapy 
of VCMF（VCR, CTX, MMC and 5-Fu）plus 
traditional medicine. A patient with rodent 
ulcer（8x5cm） once obtained complete response as to 
an approach of 5% Fu of retinoic acid ointment. A 
short CR was achieved by the protocol of 
MFC（MMC; 5-Fu; Ara C/ homoharringtonine, 
CTX）plus cantharidin or cinobufacini drug in 5 
advanced gastric cancers. One of them was a long-term 
survivor for 6 yrs via mass incision and the 
combination of MFC with herbs Scutellaria barbata d. 
don. 
In view of cancer types, 10 lymphoma was setted to the 
major protocol of the combination conventional 
chemotherapy（COMA, VCR, CTX, MMC or 
ADM）in conjunction with traditional medicine which 
to relieve the chemotherapeutic toxicity, and reinforced 
the efficacy of chemotherapy. One lymphoma was 
regressed only by prednisone（200#). Another 4 
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patients with thumb lymphadenopathy was treated by 
the use of antibiotics regimen in full dose with anti-
inflammatory herbal tablets or immunotherapy 
lymphocyte transfer factor. 
In 12 HCC, 6 HCC were treated mainly by 5-Fu (500-
1,000mg/day) and TCM. 2 patients obtained CR 
through cantharidin and traditional medicine. The main 
protocol of TCM with adjuvant antibiotics regimen and 
low dose of dexamethasone was given in a primary 
liver cancer (AFP+, ascites +++, jaundice +++, liver 
tumor 3.2x3.0cm). One acute promyelocytic leukemia 
complicated with metastatic liver cancer (7x4.5cm) was 
in CR with all-trans retinoic acid (ATRA) and TCM. 
The detail prescription of TCM was mentioned 
before
25, 26
. In the follow up, one HCC accompanied 
with colon polyps obtained complete remission via 
hapatectomy and targeting oncogenic receptor tyrosine 
kinase inhibitor sorafenib. 
Dose intensity has proven to be critical in maximizing 
chemotherapeutic efficacy for numerous human 
cancers.Eight other patients with cancers were in 
remission through small dosage of chemotherapy and 
TCM or traditional medicine（TCM）alone. There 
were 4 lung cancers, 1 gallbladder cancer,1 
cholangicarcinoma and 2 thyroid cancers. Among 
targeting two metastatic lung cancer, one female with 
lung cancer was given the combination chemotherapy 
plus targeting oncogenic receptor EGFRv III gefitinib, 
which was stable disease for 8+ months. Thyroid 
cancer was placed on the primary use of traditional 
medicine. The crude herbs consisted of sargassum, 
tangle, Oyster（mussels), Poria cocos, Ophiopogon 
japonicus, Prunella vulgaris, Taraxacum, Scrophularia 
ningpoensis, Cremastra appendiculata, Trichosanthes 
Kirilowii, Sophora subprostrata, Houttuynia cordata, 
Scutellaria barbata d. don and Oldenlandia diffusa 
roxb. 
The survival times in those patients with remission 
were less than 1 years 10 cases, 1 to 3 years 20 cases, 
over 3 to 5 years 12 cases, over 5 to 10 years 11 cases, 
over 10 to 20 years 13 cases, and over 20 years 7 cases. 
In differential types of 20 patients with over 10 years 
survivors, lymphoma occupied 8 cases（40%). Among 
7 patients with over 20 years, lymphoma occupied 3 
cases, metastatic breast cancer 2 cases and 
hepatocellular carcinoma 2 cases. 
 
CASE REPORTS 
A 55 years old woman was diagnosed as having 
metastatic palatum cancer on November 6, 1993 when 
she presented with tumors both in her cavity of the 
mouth and neck lymphadenopathy. On examination 
revealed 2 lymph nodes (4x3 cm) enlargement in her 
left neck. A 3x5cm mass was found in her palate molle 
which was covered over uvula palatina. Moreover, the 
left side of her face also had a thumb lymph nodes 
palpable. Cures can be achieved by use of combination 
chemotherapy (VCR, CTX, 5-Fu, phytohemagglutinin, 
PHA) and in 18 years later she died of recurrent 
episodes of oral cancer. 
A 43-year-old man entered the hospital due to his 
metastatic nasopharynx cancer on July 4, 1995. At first 
onset he developed symptoms of marked headache, 
right neck lymphadenopathy (thumb size).The patient 
received no radiotherapy. With the relief symptoms of 
headache and regression of his lymphadenopathy, the 
diplopia and unable version in his eye were recovered 
to "normal" visual acuity under the combination 
chemotherapy of VCMF (VCR, CTX, MMC, 5-Fu) 
with the addition of TCM. He obtained a 3years 
survivor. 
A 35-year-old woman was admitted to the hospital 
because of her relapsed gastric cancer, with recurrent 
fever for one month duration. In March, 1996 she was 
undergoing surgery in a local hospital due to her tarry 
stools. At post-operatively, a rodent 
ulcer（5x4x2.8cm）with harden border was detected 
in lesser curvature of the stomach, accompanied with 
adjacent metastatic lymph nodes.NHL was diagnosed 
according to her stomach tissue specimens. The 
definitive diagnosis of her malignant tumor was based 
on a provincial tumor hospital. She had a past history 
of tuberculosis.CR was obtained after small dosage of 
MFC（5-Fu, MMC, CTX）in combination with 
cinobufacini intravenously, oral daily 
demethylcantharidin and traditional herbs. As an 
outpatient, she had continued to traditional herbs 
Scutellaria barbata d. don. She was a long-term 
survivor for 6 years and died of tuberculosis（type IV). 
A 58-year-old man was diagnosed as having malignant 
lymphoma on April 29, 1997. He presented his past 
history of lymph node palpable (a pea size) in right 
neck region 8 years ago. Later in 1995, a gradually 
increased thumb lymph node was palpable, 
accompanied by his left neck metastasis. At physical 
examination, on admission, showed 4.5x3cm, 2x3cm, 
2x3cm palpable lymph node in right neck and a 2x3cm 
lymph node in left neck region. Lymphoma was 
diagnosed according to his lymph node aspirates. He 
obtained remission following combination 
chemotherapy（CTX and 5-Fu）in conjunction with 
traditional medicine. He was stable disease with tumors 
for 12 years survivor. 
A 75-year-old woman entered the hospital due to her 
metastatic nasopharynx cancer in June, 1997. On 
admission she presented with anemia following 
melena, fatigue and weakness. A thumb lymph node 
behind her right ear was palpable. CR was obtained 
through TCM and small dosage of 
chemotherapy（CTX and 5-Fu, and enlarged lymph 
node was disappeared. She was a 4 years survivor. 
Traditional medicine consisted of Prunella vulgaris, 
asparagalus membranaceus, rehmannia glutinosa, 
ophiopogon japonicus, lyceum chinenses, centipede, 
cantharides, scutellaria barbata d.don, oldenlandin 
diffusa roxb. 
A 71-year-old man was admitted to the hospital on 
December 29, 1997 because of the relapse of his 
lymphoma for 2 months duration. He once obtained 
partial remission（PR）using chemotherapy in another 
tumor hospital.CR was obtained by the main protocol 
of TCM with small dosage of chemotherapy（CTX, 5-
Fu). TCM consisted of asparagalus membranaceus, 
ophiopogon japonicus, asparagus, coix lachryma, paris 
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polyphylla, pseudobulb of appendiculate cremastra, 
trichosanthes kirilowii, indigowoad leaf, scutellaria 
barbata d. don, oldenlandia diffusa roxb. He was a 
survivor of 7 yrs. 
A 62-year-old woman entered the hospital because of 
her chronic myelocytic leukemia (CML) on October 
21, 2000. She developed her distended abdomen and 
splenomegaly 6 months duration. On B ultrasound 
examination showed that spleen reached to umbilicus, 
with irregular liver scan. Hemoglobin concentration 
was 70g/L. leukocyte count 160,000 (160x109/l) with 
19% blasts and promyelocytes, 28.5% myelocytes and 
metamyelocytes. Platelet count was 375x109/l. Bone 
marrow aspirations revealed marked hypercellularity 
with myeloid hyperplasia. Blast forms (blast and 
promyelocytes) constituted approximately 19.6% of all 
cells, and immature myelocyte and metamyelocytes 
occupied 28.5% of all cells. Megakaryocytes was 
hyperplasia. The diagnosis of CML with accelerate 
stage was made.CR was obtained after busulfan in 
conjunction with TCM. She was in satisfactory health 
until 4 years before admission. When she was found to 
be splenomegaly. At that time, WBC 120x109/l. The 
high percentage of blast cells corresponded to the 
beginning of her relapse. Oral busulfan was 
administered in the following a total dose of 120mg, 
with CR again. She was survivor for near 8 years. 
A 65-year-old woman was diagnosed as having 
gallbladder cancer in July 20, 2002. She developed 
symptoms of lancinating abdominal pain and intensive 
distended abdomen and tender with muscle defense in 
upper quadrants. On CT scan demonstrated that her 
ascites+++, gallbladder was dilation, with irregular 
thick cholecystic inner wall, and many nodules were 
found in the cavity of bile. She was given the 
combination of TCM with small dosage of 5-Fu and 
CTX drugs. Three months later, in view of 
improvement of her general symptoms, she obtained 
CR. She is in health during follow up of 15years. 
A 25-year-old man was admitted to the hospital on 
October 4, 2003 because of his relapsed malignant 
lymphoma. He complained of his enlarged lymph 
nodes once regression using herbs in 1997. He had a 
past experience of combination chemotherapy due to 
lymph node enlargement in bilateral neck, which was 
diagnosed as having malignant lymphoma（B cell 
type. In September, 2003, he developed his 
nasopharynx the markedly inflamed redness, swelling, 
and with obstruction. At physical examination revealed 
5 firm lymph nodes to varying degree in size of a pea 
to a walnut in his left neck, and 2 palpable lymph 
nodes（1.5x2cm）in his right neck. A 3x4.5cm mass 
was found in his soft palate molle which was flecked 
with small red ulcer patches. CR can be achieved by 
use of antibiotics regimen in full dose and combination 
chemotherapy（VCR, CTX, 5-Fu, MMC), the tumors 
was disappeared as like the mouth of health 
individuals. He was a 3 years of survivors. 
A 72-year-old man was admitted to the hospital due to 
his jaundice cholangio carcinoma on September 2, 
2004. He had a history of bad cough two months ago, 
followed by a progressive general jaundice, 
conspicuous weight loss, and no appetite and urine 
icterus. On CT examination showed his complete 
obstructive choledodus and his cholangiectasis due to 
the cause of obstructive tumor (1.5x2cm). He was 
given the treatment of antibiotics in full dose, 
combinatiion chemotherapy (5-Fu, CTX, MMC) with 
TCM. CR was achieved two months later, and as an 
outpatient, he was to be continued the traditional herbs. 
Traditional medicine consisted of  astragalus 
membranaceus, ophiopogon japonicas, asparagus, 
poria cocos, lyceum chinenses, wheat sprout, salvia 
bowleyana, scutellaria baicalensis, Artemisia 
capillaries, gardenia jasminoides, hypericum 
japonicum, houttuynia cordata, scutellaria barbata d. 
don, oldenlandia diffusa roxb. 
A 38-year-old woman was admitted to the hospital on 
September 26, 2004 due to palpable lymph nodes in her 
neck for 1+ year duration. One year before admission 
to the hospital she accidentally noted lymphadenopathy 
in her bilateral neck region, and lymph node 
enlargement regressed with unknown drugs. In July, 
2003, she presented no efficacy following treatment 
because of her lymphadenopathy relapsed. When 
examined, there were 6 lymph nodes palpable in her 
left neck, with varied degree in size of a pigeon's egg to 
a pea or thumb size. Scrofula with caseous necrosis 
was diagnosed according to her lymph node aspirates. 
TB-Ab negative. Remission was obtained through anti-
TB regimen in combination with TCM. TCM consisted 
of Prunella vulgaris, traxacum, honeysuckle, 
ophiopogon japonicus,asparagus, mussels, coix 
lachryma, houttuynia cordate, scutellaria barbata d. 
don, oldenlandia diffusa roxb. In the follow up, she 
was a 15 years survivor. 
A 58-year-old man was diagnosed as having chronic 
lymphocytic leukemia（CLL）on January 16, 2011 
because of recent leukocyte counts elevated to 
118x109/l. The patient complained of his 
leukocytosis（67-97x109/l）for more than one month 
duration. He was treated with hydroxycarbamide in 
another hospital and leukocytosis declined to 27x109/l. 
The most common physical signs revealed two thumb 
lymph nodes palpable in his left neck. Hemogram: 
Hemoglobin concentration（Hb）was 87g/l. 
Leukocyte count（WBC）123.88x109/l. The 
leukocyte differential count: 9% segmented 
neutrophils, 90% small lymphocytes. The platelet count 
131x109/l. Bone marrow aspiration revealed 
hypercellularity. Bone marrow differential count:14% 
myeloid, 7.2% erythroid, approximately 76.8% of 
predominant cell was small lymphocytes. The 
diagnosis of CLL was made. CR was obtained by the 
use of chlorambucil tablets and traditional medicine. 
On April 9, 2011, repeat hemogram: Hb 112g/l, WBC 
13.6x109/l, plt 128x109/l. On May 5 and July 28, 2011, 
Hb 104-112g/l; WBC 9.54-10.1x109/l, with a 
leukocyte differential count of 26.2% mature 
neutrophils and 63.8% lymphocytes; plt 101-112x109/l 
respectively. Bone marrow aspirates on May14, 2011 
revealed normal cellularity. Bone marrow differential 
count: 34% myeloid, 31.2% erythoid, 33.6% 
lymphocytes. As an outpatient, he continued traditional 
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herbs. He was well until on October 15, 2011 while an 
attack of stomach pain and tarry stools was admitted to 
another hospital. Routine hematologic studies at that 
time, Hb 69g/l; WBC 7.3x109/l with 70% mature 
neutrophils and 28% lymphocytes; plt 188x109/l. 
Repeat bone marrow aspirates on October 15, 2011 
revealed normal cellularity. Bone marrow differential 
counts: 50% myeloid, 21% erythroid, 27.5% 
lymphocytes. He died of another stomach cancer. 
 
DISCUSSION 
In this study, a series of the long follow up of patients 
with cancers were reported. I experienced that a CR 
was a pivotal influencing factor in those longest 
survival patients, and traditional medicine was also 
recommended. 
The traditional combination chemotherapy program for 
lymphomas of favorable histologic type has been CVP 
(CTX, VCR, Pred) given at 21-days intervals
29
. 
Cyclophosphamide, vincristine, procarbazine, and 
prednisone (COPP) were used in the NCI study for 
patients with nodular mixed and nodular histocytic 
lymphomas
30
. More intensive CVP programs with the 
addition of Adriamycin or bleomycin, or both, known 
as BACOP or CHOP-bleo, resulted in overall complete 
remission rates for patients with diffuse lymphomas 
ranging from 48% to 89%
31-34
. The NCI program of 
this 5-drug program, complete remission rates with 
these approaches has ranged from 48% to 94%
33
. In 
this study, the CR rates was 63% in 16 lymphomas, 6 
CR were used by CVP or COMA regimens. 
The use of chemotherapy to treat stomach cancer has 
no firmly established standard of care
35
. Some drugs 
used in stomach cancer treatment have included: 5-Fu 
(fluorouracil), doxorubicin (Adriamycin), mitomycin C 
and most recently oxaliplatin, irinotecan in various 
combination. The relative benefits of these different 
drugs, alone or in combination, are unclear
36
. There are 
evidences supporting that clinical researches are 
exploring the benefits of giving chemotherapy as 
adjuvant therapy for surgery to destroy remaining 
cancer cells
37
. In recent analyses of definitive surgery 
followed by adjuvant radio chemotherapy (5-
Fu/leucovorin LV regimens) for patients with gastric 
cancer, Liu and Ahmed reported that 59.3% (48/81) 
patients survived > 3 years, 18.5% (15/81) patients 
survived 5 or more years
38
. Eighteen out of 81(22.2%) 
patients are still alive with a medium survival of 142 
months (57-196 months). In this study, 5 patients with 
gastric cancer obtained a short CR through MFC 
regimen plus cinobufacini and cantharidin drugs. One 
relapsed gastric cancer survived over 6 years after 
surgery and adjuvant chemotherapy. More recent, 
treatment with HER2 inhibitor, trastuzumab, has been 
demonstrated to improve overall survival in inoperable 
locally advanced or metastatic gastric carcinoma 
overexpressing the HER2
37
. Oncogenic receptor 
HER2
39
 is over expressed in 13-22% of patients with 
gastric cancer
40,41
. Tanz and colleagues reported two 
HER2-positive metastatic gastric adenocarcinoma who 
favorably responded to second line chemotherapy 
(FOLFIRI, irinotecan plus 5-Fu) with trastuzumab 
continuation following progressive disease to first line 
treatment containing trastuzumab, implicating 
trastuzumab continuation in metastatic HER positive 
gastric cancer is safe, practical and improve survival
42
. 
Oncogenic EGFR mutations are found in 10% to 35% 
of lung adenocarcinomas, with predominants in a 
subset of patients with non-small cell lung 
cancer（NSCLC)43-49. These mutations, which 
commonly occur as either small in-frame deletions in 
exon 19 or point mutations T790M or L858R in exon 
21 within the EGFR tyrosine kinase domain, confer 
constitutive activity and sensitivity to EGFR tyrosine 
kinase inhibitor（TKI)49,50. Konduri and colleagues 
reported five patients with metastatic lung cancer 
whose tumors harbored EGFR fusion, most commonly 
RAD5, are recurrent in lung cancer. Four of whom 
were treated with EGFR TKI erlotinib with 
documented antitumor response for 5, 6, 8, and 20 
months respectively
51
. An early EGFR TKI trial 
randomized patients with EGFR mutation positive 
stage IIIb or IV adenocarcinoma to treatment with 
afatinib or gemcitabine and cisplatin, treatment with 
afatinib prolonged progression free survival to 11.0 
months as opposed to 5.6 months with gemcitabine and 
cisplatin
6
. In the phase III trial of 419 patients with 
advanced T790M positive NSCLC with osimertinib vs 
platinum based therapy, progression free survival in the 
osimertinib group was 8.5 months, compared to the 
platinum-based therapy group at 4.2 months
6
. Serra 
reported the clinical response of a lapatinib-based 
therapy in lung metastatic lesions of a Li-Fraumeni 
syndrome patient with oncogenic HER2V659E 
mutation and an EGFR-exon 20 insertion. A 
symptomatic and radiologic clinical response was 
achieved using oral daily lapatinib at a dose of 
1,000mg in combination with intravenous weekly 
paclitaxel 80mg/m
2
, lately, trastuzumab initial dose of 
8mg/kg intravenously, and then followed by 6mg/kg 
every three weeks
52
. In total, the clinical benifits lasted 
over 9 months. In Cuba, CimaVax-EGF, promising, an 
active vaccine targeting EGF as the major ligand of 
oncogenic EGFR, it is in use as a cancer therapy 
against non-small cell lung cancer（NSCLC)53,54. In 
this study, we use gefitinib in keeping stable disease for 
8+ months in a woman with lung adenocarcinoma, and 
using gefitinib in more patients are under investigation. 
Interesting, in an APL complicated with secondary 
HCC, It has been demonstrated previously that nuclear 
RARB has been shown to be rearranged as a result of 
insertion of HBV sequences
55
. Recent promising, these 
oncogenic receptor derivatives
23, 56-58








 were also 
detected in APL rare cases. The involvement of RARB 
may explain why the disappearance of malignant 
hepatic tumour cells via the use of ATRA agent. In this 
case, ATRA (80-100mg/ day) was resistance to the 
relapse episode. In the presence of genetic mutation in 
RARA LBD and the PML-B2 domain of PML-RARA, 
one explanation for ATRA resistance is that the N-
CoR/ SMAT-corepressor complex tightly interact with 
pml/ RARA or PLZF, even under pharmacological 
concentration of ATRA, so that transcriptional de-
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repression cannot occur at RARA target gene promoter, 
ATRA binding LBD impaired, degradation of pml/ 
RARA by proteasome pathway are inhibited
23, 63
. 
Previous studies uncovered that the ATRA and 13-cis 




In addition, new emerging aberrant pml/ RARA in 




normal retinoid signaling and RAR function, 
suppressing (the blockade of) differentiation, 
possessing an altered specifity for DNA response 
element, these DNA recognition changes target a 
distinct set of "neoplastic" genes that differ from the 
genes normally targeted by normal RARA. In literature 
alternative strategy, an APL obtained CR after 
treatment with 13-cis retinoic acid first and repeated 
CR with ATRA in relapse
65
. And more, 80% (4/5) CR 
in newly APL and 33% (4/12) CR in relapsed APL 
were achieved after treatment with 9-cis retinoic acid 
(LGD1057) alone
66
. Nowadays, a lot of cohort trials, 
61.5% (24/39) achieved CR using tamibarotene 
including 5 newly APL and 13 relapse APL twice or 
more
67-73
. Among 269 APL with CR underwent 
maintenance random, four year relapse-free survival 
rate was 84% (ATRA) and 91% (Tamibarotene). In 52 
high risk patients, this became significant (50% for 
ATRA, 87% for tamibarotene)
72
. In comparative 
analysis among those relapsed APL
74
, 80%(28/35) 
achieved CR and 22.86% CRm in tamibarotene-ATO 
versus 54.2% (19/35)CR with only 2.86-3.7% CRm in 
ATRA and ATO regimen
73
. In particular, an 
appreciable benefits of tamibarotene-ATO regimen 
might occur at significantly lower frequency of 
leukocytosis with development of retinoic acid 
syndrome, an important adverse reaction during 
treatment of APL. Thus, Tamibarotene demonstrated 
more efficacy in both untreated APL patients and 
relapsed who have been treated ATRA and 
chemotherapy, especially as novel strategy in relapsed 
APL in Japan and others
74-76
. This is encouraging 
perspective. 
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Sex Mean ages (years) Treatment Protocol 
 
Response following therapy Duration of remission(years) 
< 1  1-3 > 3-5 >5-10 >10   









 1       3        2       1        9 
HCC 12 M10, 
F2 
44.0(26-63) a.5-Fu(250-1,000mg/ day), 
VCR,CTX,MMC,TCM 
b. Cantharidin, TCM 
c. hepatectomy, sorafenib 
CR(8), 
Short CR(2), PR(1), 
stable disease(1) 
 1       4       1        3       3 
Lung tumors 12 M8,F4 60.1(40-79) a. COMF, TCM;  
 b.DDP, etoposide, IL-2/gefitinib; 
c.CTX,5-FU, antitumor capsule; 
d.TCM alone   
CR(2), 
short CR(2), PR(3), 
stable disease (5) 
   4       3                 3        1 
NPC 5 M3, F2 51.4(38-75) a. VCMF, TCM 
b.CTX,5-FU,TCM 
CR(1), short CR(1), PR(3)     1       3        1 
MBC 4 F4 31.3(25-41) a. COMF, TCM 
b.COP, TCM 
CR(3),PR(1)                        1                  2 
Stomach 
cancer 
5 M2, F3 42.3(35-500 a.MFC, TCM;    b.CTX, 5-FU, 
antitumor capsule 
CR(1),short CR(2),PR(2)           1        3                 1 
AML 3 M2, F1 4, 18, 20 DA**, HA, TCM PR(3)           3 
APL 1 M 31 ATRA   80mg/day; 
H 1mgx5days;  TCM    
CR 1 
           died of relapsed APL 
CML 2 M1, F1 33, 62 Busulfan, TCM CR (1), 
short CR(1) 
                 1       1 
CLL 1 M 58 Chlorambucil, TCM CR                      1  
died of stomach cancer 
MM 2 M1, F1 60, 63 Thalidomide, pred, TCM Short CR(1), 
PR(1) 
1        1 
Epidermoid 
cancer 
1 F 72 5% FU of retinoic  acid ointment PR 1 
Thyroid 
cancer 
2 F2 54, 60 TCM alone CR(2)                            1                1 
Bile cancer 1 F 65 CTX,5-FU,TCM CR                                               1 
Cholangio-
carcinoma 
1 M 72 MFC （MMC，5-
FU，CTX），TCM 
CR                       1 
died of intestinal cancer 
Others*** 7 M5,F2 57.5(44-69) COFP,COMMB,TCM CR(1), PR(6)                   1        2       1       3 
Note: HCC: hepatocellular carcinoma; NPC: metastatic nasopharyngeal cancer; MBC: metastatic breast cancer; AML: acute myeloid leukemia; APL: acute promyelocytic leukemia; CML: chronic myeloid leukemia; CLL: 
chronic lymphocytic leukemia; MM: multiple myeloma; COMA:CTX, VCR, MMC, ADM;  COMF: CTX, VCR, MMC/ADM, 5-FU; VCMF:VCR,CTX, MMC/DDP; 5-FU; COP: CTX, VCR, pred; COFP:CTX, VCR,  
5-FU, PHA, Pred;  DA:DNR, 45mg/m2, Ara-c 100mg/m2; HA: homoharringtone 1mg x 5days,ara-c 50mg,intramuscle,twice a day; MFC:MMC,5-FU,Ara-c/H,CTX; COMMB: CTX, VCR, MMC, MTX, Bleomycin; ATRA: all-
trans retinoic acid; Pred: prednisone; TCM: traditional medicine; M:male; F:female. *: cases number; **: treatment in another hospital; ***include oral cancer 1, relapsed vulva cancer 1, laryngeal cancer 1, maxillary sinus 
carcinoma 1, carcinoma of mandibular sinus 2, and metastatic bone tumor 1. 
 
